{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:18:17Z","timestamp":1772821097374,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-025-09309-4","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T04:34:24Z","timestamp":1764822864000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of the effect on treatment satisfaction of switching from multiple insulin injection therapy to additional administration of imeglimin in subjects with type 2 diabetes (MEGMI-TS): study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison trial"],"prefix":"10.1186","volume":"27","author":[{"given":"Hiroya","family":"Kitsunai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nanbu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumika","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tasuku","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Takiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiga","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Shukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Takiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayaka","family":"Kurigaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumi","family":"Takiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuko","family":"Abiko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiko","family":"Homma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuminori","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0713-221X","authenticated-orcid":false,"given":"Hiroshi","family":"Nomoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"issue":"2","key":"9309_CR1","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2337\/diacare.22.2.233","volume":"22","author":"M Coutinho","year":"1999","unstructured":"Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22(2):233\u201340.","journal-title":"Diabetes Care"},{"issue":"11","key":"9309_CR2","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753\u201386.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"9309_CR3","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/dc24-S009","volume":"47","author":"American Diabetes Association Professional Practice C","year":"2024","unstructured":"American Diabetes Association Professional Practice C. 9. Pharmacologic approaches to glycemic treatment: standards of care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S158\u201378.","journal-title":"Diabetes Care"},{"issue":"2","key":"9309_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/0168-8227(95)01064-K","volume":"28","author":"Y Ohkubo","year":"1995","unstructured":"Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103\u201317.","journal-title":"Diabetes Res Clin Pract"},{"key":"9309_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/pdi.1618","author":"A Garmo","year":"2011","unstructured":"Garmo A, Garmo H, \u00c4rnl\u00f6v J, Leksell J. Long\u2010term treatment effects of insulin pump therapy. Pract Diab. 2011. https:\/\/doi.org\/10.1002\/pdi.1618.","journal-title":"Pract Diab"},{"issue":"4","key":"9309_CR6","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jdiacomp.2017.11.011","volume":"32","author":"AH Abdelhafiz","year":"2018","unstructured":"Abdelhafiz AH, Sinclair AJ. Deintensification of hypoglycaemic medications-use of a systematic review approach to highlight safety concerns in older people with type 2 diabetes. J Diabetes Complications. 2018;32(4):444\u201350.","journal-title":"J Diabetes Complications"},{"issue":"7","key":"9309_CR7","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1111\/dom.13724","volume":"21","author":"S Seidu","year":"2019","unstructured":"Seidu S, Kunutsor SK, Topsever P, Hambling CE, Cos FX, Khunti K. Deintensification in older patients with type 2 diabetes: a systematic review of approaches, rates and outcomes. Diabetes Obes Metab. 2019;21(7):1668\u201379.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"9309_CR8","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.2337\/dc12-0413","volume":"35","author":"SE Inzucchi","year":"2012","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364\u201379.","journal-title":"Diabetes Care"},{"issue":"9","key":"9309_CR9","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/j.1463-1326.2012.01611.x","volume":"14","author":"V Pirags","year":"2012","unstructured":"Pirags V, Lebovitz H, Fouqueray P. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diabetes Obes Metab. 2012;14(9):852\u20138. https:\/\/doi.org\/10.1111\/j.1463-1326.2012.01611.x.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"9309_CR10","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/dom.14277","volume":"23","author":"S Hallakou-Bozec","year":"2021","unstructured":"Hallakou-Bozec S, Vial G, Kergoat M, Fouqueray P, Bolze S, Borel AL, et al. Mechanism of action of Imeglimin: a novel therapeutic agent for type 2 diabetes. Diabetes Obes Metab. 2021;23(3):664\u201373.","journal-title":"Diabetes Obes Metab"},{"key":"9309_CR11","doi-asserted-by":"crossref","unstructured":"Fouqueray P, Leverve X, Fontaine E, Baqui\u00e9 M, Wollheim C. Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of type 2 Diabetes. J Diabet Metab. 2011;02(04):126.","DOI":"10.4172\/2155-6156.1000126"},{"issue":"3","key":"9309_CR12","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s40268-015-0099-3","volume":"15","author":"V Vuylsteke","year":"2015","unstructured":"Vuylsteke V, Chastain LM, Maggu GA, Brown C. Imeglimin: a potential new multi-target drug for type 2 diabetes. Drugs R D. 2015;15(3):227\u201332.","journal-title":"Drugs R D"},{"issue":"5","key":"9309_CR13","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/dom.14642","volume":"24","author":"C Reilhac","year":"2022","unstructured":"Reilhac C, Dubourg J, Thang C, Grouin JM, Fouqueray P, Watada H. Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): a randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period. Diabetes Obes Metab. 2022;24(5):838\u201348. https:\/\/doi.org\/10.1111\/dom.14642.","journal-title":"Diabetes Obes Metab"},{"key":"9309_CR14","unstructured":"Bradley C: The Diabetes Treatment Satisfaction Questionnaire: DTSQ. In Handbook of Psychology and Diabetes: a guide to psychological measurement in diabetes research and practice. Edited by Chur BC. Switzerland: Harwood Academic Publishers; 1994:111\u2013132."},{"issue":"7","key":"9309_CR15","first-page":"809","volume":"192","author":"H Ishii","year":"2000","unstructured":"Ishii H, Bradley C, Riazi A, Barendse S, Yamamoto T. The Japanese version of the Diabetes Treatment Satisfaction Questionnaire (DTSQ): translation and clinical evaluation. J Clin Exp Med. 2000;192(7):809\u201314.","journal-title":"J Clin Exp Med"},{"issue":"2","key":"9309_CR16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/1098-108X(198602)5:2<295::AID-EAT2260050209>3.0.CO;2-T","volume":"5","author":"T van Strien","year":"1986","unstructured":"van Strien T, Frijters JER, Bergers GPA, Defares PB. The Dutch Eating Behavior Questionnaire (DEBQ) for assessment of restrained, emotional, and external eating behavior. Int J Eat Disord. 1986;5(2):295\u2013315.","journal-title":"Int J Eat Disord"},{"issue":"3","key":"9309_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s13340-020-00439-5","volume":"11","author":"E Araki","year":"2020","unstructured":"Araki E, Goto A, Kondo T, Noda M, Noto H, Origasa H, et al. Japanese clinical practice guideline for diabetes 2019. Diabetol Int. 2020;11(3):165\u2013223. https:\/\/doi.org\/10.1007\/s13340-020-00439-5.","journal-title":"Diabetol Int"},{"issue":"3","key":"9309_CR18","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s13300-020-00986-9","volume":"12","author":"H Nomoto","year":"2021","unstructured":"Nomoto H, Oba-Yamamoto C, Takahashi Y, Takeuchi J, Nagai S, Yokoyama H, et al. Effects of switching from Liraglutide or Dulaglutide to subcutaneous Semaglutide on glucose metabolism and treatment satisfaction in patients with Type 2 diabetes: protocol for a multicenter, prospective, randomized, open-label, blinded-endpoint, parallel-group comparison study (the SWITCH-SEMA 1 study). Diabetes Ther. 2021;12(3):955\u201364. https:\/\/doi.org\/10.1007\/s13300-020-00986-9.","journal-title":"Diabetes Ther"},{"issue":"2","key":"9309_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1507\/endocrj.EJ17-0303","volume":"65","author":"M Oita","year":"2018","unstructured":"Oita M, Miyoshi H, Ono K, Nakamura A, Cho KY, Nomoto H, et al. Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes-randomized controlled study. Endocr J. 2018;65(2):141\u201350. https:\/\/doi.org\/10.1507\/endocrj.EJ17-0303.","journal-title":"Endocr J"},{"issue":"5","key":"9309_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197663","volume":"13","author":"T Okura","year":"2018","unstructured":"Okura T, Nakamura R, Fujioka Y, Kawamoto-Kitao S, Ito Y, Matsumoto K, et al. CPR-IR is an insulin resistance index that is minimally affected by hepatic insulin clearance-A preliminary research. PLoS ONE. 2018;13(5):e0197663. https:\/\/doi.org\/10.1371\/journal.pone.0197663.","journal-title":"PLoS ONE"},{"key":"9309_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071838","author":"H Nomoto","year":"2023","unstructured":"Nomoto H, Kito K, Iesaka H, Oe Y, Kawata S, Tsuchida K, et al. Favorable effect of Pemafibrate on insulin resistance and \u03b2-cell function in subjects with type 2 diabetes and hypertriglyceridemia: a subanalysis of the PARM-T2D study. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15071838.","journal-title":"Pharmaceutics"},{"key":"9309_CR22","doi-asserted-by":"publisher","DOI":"10.2337\/db20-91-LB","author":"A Miyoshi","year":"2020","unstructured":"Miyoshi A, Obara S, Wada N. 91-LB: study of glycemic variability and hypoglycemia using continuous glucose monitoring in type 2 diabetes mellitus changed from basal-bolus therapy to basal-GLP-1RA therapy. Diabetes. 2020. https:\/\/doi.org\/10.2337\/db20-91-LB.","journal-title":"Diabetes"},{"issue":"14","key":"9309_CR23","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"DM Nathan","year":"1993","unstructured":"Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977\u201386.","journal-title":"N Engl J Med"},{"issue":"9131","key":"9309_CR24","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837\u201353.","journal-title":"Lancet"},{"issue":"8","key":"9309_CR25","doi-asserted-by":"publisher","first-page":"836","DOI":"10.3109\/07853890.2012.699715","volume":"44","author":"MJ Abrahamson","year":"2012","unstructured":"Abrahamson MJ, Peters A. Intensification of insulin therapy in patients with type 2 diabetes mellitus: an algorithm for basal-bolus therapy. Ann Med. 2012;44(8):836\u201346. https:\/\/doi.org\/10.3109\/07853890.2012.699715.","journal-title":"Ann Med"},{"key":"9309_CR26","doi-asserted-by":"crossref","unstructured":"Brixner D, Ermakova A, Xiong Y, Sieradzan R, Sacks N, Cyr P, et al. Clinical and Economic Outcomes of Patients with Type 2 Diabetes on Multiple Daily Injections of Basal-bolus Insulin (MDI) Therapy: A Retrospective Cohort Study. Clin Ther. 2019;41(2):303\u201313 e1.","DOI":"10.1016\/j.clinthera.2018.12.014"},{"issue":"2","key":"9309_CR27","doi-asserted-by":"publisher","first-page":"240","DOI":"10.2337\/dc09-1348","volume":"33","author":"M Peyrot","year":"2010","unstructured":"Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care. 2010;33(2):240\u20135.","journal-title":"Diabetes Care"},{"issue":"7","key":"9309_CR28","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1001\/jamainternmed.2016.2288","volume":"176","author":"MN Munshi","year":"2016","unstructured":"Munshi MN, Slyne C, Segal AR, Saul N, Lyons C, Weinger K. Simplification of insulin regimen in older adults and risk of hypoglycemia. JAMA Intern Med. 2016;176(7):1023\u20135.","journal-title":"JAMA Intern Med"},{"issue":"8","key":"9309_CR29","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.1111\/dom.15639","volume":"26","author":"A Takahashi","year":"2024","unstructured":"Takahashi A, Nomoto H, Onishi K, Manda S, Miya A, Kameda H, et al. A comparative study of the effects of imeglimin add-on or metformin dose escalation on glycaemic variability in subjects with type 2 diabetes treated with low-dose metformin (MEGMI-CGM study). Diabetes Obes Metab. 2024;26(8):3471\u20134.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"9309_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2337\/dc08-0856","volume":"32","author":"RT Anderson","year":"2009","unstructured":"Anderson RT, Girman CJ, Pawaskar MD, Camacho FT, Calles J, Kelly WS, et al. Diabetes medication satisfaction tool: a focus on treatment regimens. Diabetes Care. 2009;32(1):51\u20133.","journal-title":"Diabetes Care"},{"issue":"2","key":"9309_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.204","volume":"4","author":"S Naing","year":"2021","unstructured":"Naing S, Ramesh G, Garcha J, Poliyedath A, Khandelwal S, Mills PK. Is the stepping-down approach a better option than multiple daily injections in obese patients with poorly controlled type 2 diabetes on advanced insulin therapy? Endocrinology, Diabetes & Metabolism. 2021;4(2):e00204. https:\/\/doi.org\/10.1002\/edm2.204.","journal-title":"Endocrinology, Diabetes & Metabolism"},{"issue":"2","key":"9309_CR32","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.diabres.2008.03.020","volume":"81","author":"H Ishii","year":"2008","unstructured":"Ishii H, Anderson JH Jr., Yamamura A, Takeuchi M, Ikeda I. Improvement of glycemic control and quality-of-life by insulin lispro therapy: assessing benefits by ITR-QOL questionnaires. Diabetes Res Clin Pract. 2008;81(2):169\u201378. https:\/\/doi.org\/10.1016\/j.diabres.2008.03.020.","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"9309_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094483","volume":"9","author":"LW van Golen","year":"2014","unstructured":"van Golen LW, Veltman DJ, \u0132zerman RG, Deijen JB, Heijboer AC, Barkhof F, et al. Effects of insulin detemir and NPH insulin on body weight and appetite-regulating brain regions in human type 1 diabetes: a randomized controlled trial. PLoS One. 2014;9(4):e94483.","journal-title":"PLoS One"},{"issue":"4","key":"9309_CR34","doi-asserted-by":"publisher","first-page":"952","DOI":"10.2337\/dc20-0763","volume":"44","author":"J Dubourg","year":"2021","unstructured":"Dubourg J, Fouqueray P, Thang C, Grouin JM, Ueki K. Efficacy and safety of imeglimin monotherapy versus placebo in Japanese patients with type 2 diabetes (TIMES 1): a double-blind, randomized, placebo-controlled, parallel-group, multicenter phase 3 trial. Diabetes Care. 2021;44(4):952\u20139.","journal-title":"Diabetes Care"},{"issue":"4","key":"9309_CR35","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/dom.14613","volume":"24","author":"J Dubourg","year":"2022","unstructured":"Dubourg J, Fouqueray P, Quinslot D, Grouin JM, Kaku K. Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): a 52-week, open-label, multicentre phase 3 trial. Diabetes Obes Metab. 2022;24(4):609\u201319.","journal-title":"Diabetes Obes Metab"},{"key":"9309_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7586","volume":"346","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, G\u00f8tzsche PC, Altman DG, Mann H, Berlin JA, et al. Spirit 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.","journal-title":"BMJ"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09309-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09309-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09309-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:02:32Z","timestamp":1767837752000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-025-09309-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9309"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09309-4","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"9 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The MEGMI-TS study was registered with the Japan Registry of Clinical Trials (jRCT1011240025) prior to enrollment. The study will be conducted in accordance with the principles of the Declaration of Helsinki and its amendments. The study protocol was approved by the Asahikawa Medical University Research Ethics Committee (No. 11000290), and the current version is 1.2 (approved on 11 April 2025). Physicians in the research team will obtain written informed consent from all eligible participants. The eligibility criteria are as stated above. The Research Committee approved the written materials consisting of a participant information leaflet and a consent document. The participants will be free to ask any questions about the trial and will have the opportunity to withdraw consent at any time during the study. Subjects will be withdrawn from the study for any of the reasons listed below (Table\n                      \n                      ). Participant enrollment will take place between 22 July 2024 and 31 March 2026 at five medical institutions in Hokkaido, Japan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This manuscript does not contain any personal information of the participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Nomoto H has obtained research support from Kowa Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., and Asahi Kasei Pharma Corp., and has received honoraria for lectures from Sumitomo Pharma Co., Ltd., MSD K.K., and Novo Nordisk Pharma Ltd. Kitsunai H has obtained research support from Nippon Boehringer Ingelheim Co., Ltd. Abiko A has received honoraria for lectures from Eli Lilly Japan K.K., Mitsubishi Tanabe Pharma Corporation, Nippon Boehringer Ingelheim Co., Ltd., Novo Nordisk Pharma Ltd., and Sumitomo Pharma Co., Ltd. Nanbu T, Maruyama F, Tasuku S, Takiyama Yuri, Sasaki T, Shukuda Y, Takiyama T, Kurigaki A, Takiyama Yumi, Miyamoto Y, Homma R, and Hirano F have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}